Treatment of Tropical Pulmonary Eosinophilia
Standard Treatment Protocol
- The recommended dose of Hetrazan (diethylcarbamazine/DEC) for tropical pulmonary eosinophilia is 6 mg/kg/day divided into three doses for a minimum of 14-21 days, with the longer 21-day course preferred to reduce relapse rates 1
- Administer DEC 6 mg/kg/day divided into 3 doses daily for 14-21 days 1
- Take medication with food to improve tolerability 1
- Consider adding doxycycline 200 mg daily for 6 weeks to target the symbiotic Wolbachia bacteria 1
Critical Pre-Treatment Screening
- Screen for Onchocerca volvulus (onchocerciasis) via skin snips and slit lamp examination, or give a test dose of DEC 50 mg to detect co-infection 1
- Screen for Loa loa (loiasis) with daytime blood microscopy (10 am-2 pm) if the patient has traveled to Central/West Africa 1
- DEC is absolutely contraindicated in patients with onchocerciasis or high-load loiasis (>1000 microfilariae/ml) due to risk of blindness and fatal encephalopathy 1
- If Loa loa microfilariae are present, use corticosteroids with albendazole first to reduce microfilarial load below 1000/ml before giving DEC 2
Adjunctive Corticosteroid Therapy
- Use corticosteroids for ongoing alveolitis and to prevent pulmonary fibrosis, particularly in patients with delayed diagnosis or severe disease 2, 3
- Always exclude strongyloidiasis before initiating steroids, as corticosteroids can precipitate fatal hyperinfection syndrome 2, 3
- Standard regimen: prednisolone 20 mg/day for 5 days initially, with longer courses for chronic cases 2
Management of Treatment Failure
- Approximately 20% of patients relapse and require re-treatment 3
- Monitor for relapse with clinical symptoms and eosinophil counts 2
- Re-treatment with a second course of DEC is necessary in 20% of cases 1
- Research shows 20-40% failure rates in chronic cases with standard DEC alone 2
Clinical Context Supporting Diagnosis
- Marked eosinophilia typically >3 × 10⁹/L 3, 2, 1
- Strongly positive filarial serology for W. bancrofti or Brugia species with negative blood microfilariae 3, 2, 1
- Clinical presentation: fever, dry cough, wheeze, breathlessness (often misdiagnosed as asthma) 3, 2, 1
- Chest X-ray showing interstitial shadowing or reticulonodular infiltrates in 80% of cases 2, 1
- Pulmonary function tests showing obstructive pattern early or restrictive pattern in later stages 2
Special Populations
- Avoid DEC in pregnancy and seek expert consultation 1
- Avoid during breastfeeding; expert consultation recommended 1
- For children 12-24 months, discuss with an expert before treatment 1
Monitoring During Treatment
- Watch for adverse reactions including fever, lymphadenitis, and allergic reactions 1
- Symptoms typically resolve rapidly following DEC treatment 3